Andrew Bellinger is CMO & CSO at Verve Therapeutics, Inc. (VERV). They have made 7 open-market trades across 1 company since 2021, most recently 2022-12-14.
CIK 0001864116
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $95K since 2021, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VERV | 42,629 | $474K |
Shares reported on the most recent Form 4, priced at the 2022-12-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERV | SELL | 2022-12-01 | 2022-12-02 | $22.95 | $20K | +7.7% | -10.0% | -4.0% |
| VERV | SELL | 2022-10-28 | 2022-11-01 | $39.90 | $399K | -25.8% | -38.0% | -40.2% |
| VERV | SELL | 2022-09-23 | 2022-09-27 | $35.34 | $4.2M | -2.5% | +4.7% | -48.0% |
| VERV | SELL | 2022-07-20 | 2022-07-22 | $34.90 | $698K | -11.9% | +8.9% | +4.3% |
| VERV | SELL | 2022-07-13 | 2022-07-15 | $24.90 | $249K | +17.9% | +51.1% | +30.0% |
| VERV | SELL | 2021-12-22 | 2021-12-27 | $38.70 | $1.2M | -19.2% | -24.4% | -40.8% |
| VERV | BUY | 2021-06-21 | 2021-06-21 | $19.00 | $95K | +43.6% | +46.5% | +39.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.